Photo by satheeshsankaran from unsplash
The Guillain–Barré syndrome (GBS) is an acute, immune‐mediated disease of peripheral nerves. Plasmablasts and plasma cells play a central role in GBS by producing neurotoxic antibodies. The standard treatment for… Click to show full abstract
The Guillain–Barré syndrome (GBS) is an acute, immune‐mediated disease of peripheral nerves. Plasmablasts and plasma cells play a central role in GBS by producing neurotoxic antibodies. The standard treatment for GBS is high‐dose intravenous immunoglobulins (IVIg), however the working mechanism is unknown and the response to treatment is highly variable. We aimed to determine whether IVIg changes the frequency of B‐cell subsets in patients with GBS.
Keywords:
plasmablasts patients;
guillain barr;
patients guillain;
induced plasmablasts;
barr syndrome;
ivig induced
Journal Title: Annals of Clinical and Translational Neurology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Annals of Clinical and Translational Neurology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!